PCSK9 conjugated liposomes for targeted delivery of paclitaxel to the cancer cell: A proof-of-concept study
Open Access
- 15 July 2022
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 153, 113428
Abstract
No abstract availableKeywords
Funding Information
- Comisión Nacional de Investigación Científica y Tecnológica (3180250)
- Agencia Nacional de Investigación y Desarrollo
This publication has 58 references indexed in Scilit:
- Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A ReviewJournal of Drug Delivery, 2013
- Nanoparticles in Biological SystemsAngewandte Chemie International Edition, 2011
- Production of the anticancer drug taxol in Taxus baccata suspension cultures: A reviewProcess Biochemistry, 2011
- Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in HumansArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Targeted Delivery of Protein Drugs by NanocarriersMaterials, 2010
- Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacyAdvanced Drug Delivery Reviews, 2009
- Tumor-Specific Anti-Nucleosome Antibody Improves Therapeutic Efficacy of Doxorubicin-Loaded Long-Circulating Liposomes against Primary and Metastatic Tumor in MiceMolecular Pharmaceutics, 2008
- Molecular biology of PCSK9: its role in LDL metabolismTrends in Biochemical Sciences, 2007
- Proprotein convertases: lessons from knockoutsThe FASEB Journal, 2006
- Cremophor ELEuropean Journal of Cancer, 2001